Cancer as a terrible disease ranks among the most important healthcare issues confronting humanity, necessitating a proactive approach to treatment. Numerous signaling cascades are involved in the complex process of carcinogenesis. Despite its success, chemotherapy has had some undesirable side effects. Plants offer a rich source of novel substances and represent an exciting new option for cancer research. Plants and plant-derived products are revolutionizing themselves because they are less poisonous, quicker, cheaper, safer, and simpler than standard treatment procedures. Natural products are viewed as viable candidates for the creation of anticancer medicines because of their pleiotropic effects on target events in a variety of ways. The actions of plant-derived products are selective; they damage cancer cells and have no significant effect on healthy cells. Several researches are being conducted on the production of potential candidates from these plant-derived products that can stop or inhibit cancer cell proliferation without causing adverse effects. Numerous plant-derived products and the analogs from which they were derived have been identified as potential anticancer therapeutic possibilities. In this review, we summarize research on botanical products with significant and active anticancer activity and their anticancer constituents, with a focus on breast cancer. This review sought to highlight the most recent advances and key successes in plant-derived products and cancer therapies focusing on nuclear and cellular structures. Furthermore, cancer drugs and their problems are discussed.

Ataxia-telangiectasia (A-T) is a multi-system disorder, resulted from the mutation in the ATM gene. Its mortality is largely related to some other disorders. Therefore, the management of its complications significantly improves patient quality of life. We studied a pediatric patient with A-T who one of his relatives had A-T.